|By Business Wire||
|October 10, 2012 04:38 PM EDT||
BiomarkerBase™, the first available database of every biomarker currently in active clinical use, has launched today at http://www.biomarkerbase.com.
Molecular biomarkers are rapidly changing the landscape of modern medicine, and until now there has not been a comprehensive resource for reviewing biomarkers in active clinical use, and for easily referencing information about biomarker-associated proteins, genes, diseases, and drugs.
BiomarkerBase™ has been kept purposely clean and easy to use, with all of the essential information provided about each biomarker, and with the ability to very quickly access the most detailed information available. Biomarkers can be browsed by disease, drug, or target, and all records are linked directly to primary sources such as scientific databases, FDA records, and drug labels.
“We are entering an age when diseases and drugs will be ever more precisely diagnosed and prescribed,” said John Audette, President of Amplion Research, ”and molecular biomarkers are the primary drivers behind these advances.”
BiomarkerBase™ was developed for drug and diagnostic test developers, students and post-docs, market analysts, technology transfer professionals, and even private individuals.
Many future enhancements are planned for BiomarkerBase™, including the addition of biomarkers in active clinical trials, and commercial information for diagnostic tests, drugs, and the companies that manufacture them. Users will also soon be able to run reports querying the database from a variety of perspectives.
About Amplion Research
Amplion Research develops novel information solutions that support investments in biomarker discovery, development and commercialization. BiomarkerBase™ is the company’s first product, and future products include Emerging Biomarkers™, a trend analysis tool for newly discovered and developing biomarkers, plus multiple syndicated research reports.